Drug targets stomach cancer gene 'addiction'

Testing cancers for 'addiction' to a gene that boosts cell growth can identify patients who may respond to an experimental targeted drug, according to research by a team at the ICR and The Royal Marsden

6.6 months

the median progression-free survival in stomach cancer patients who responded to FGFR inhibitor drug AZD4547

"This is a great example of a faster, smarter treatment being delivered to a relatively small but important group of patients with gastric cancer"